New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 11, 2014
04:55 EDTSTAA, STAA, STAA, VTL, VTL, VTL, ANAC, ANAC, ANAC, PTCT, PTCT, PTCT, SGMO, SGMO, SGMO, RNA, RNA, RNA, BLUE, BLUE, BLUE, BIND, BIND, BIND, FCSC, FCSC, FCSC, CRDC, CRDC, CRDC, DRTX, DRTX, DRTXWedbush to hold a conference
Life Sciences Management Conference to be held in New York on August 12-13.
News For DRTX;CRDC;FCSC;BIND;BLUE;RNA;SGMO;PTCT;ANAC;VTL;STAA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 31, 2015
10:11 EDTVTLHigh option volume stocks
High option volume stocks: CMPR TPX WMC YRCW VTL HBI RNG MXWL GLF EXPE
July 30, 2015
16:39 EDTPTCTPTC Therapeutics reports Q2 EPS ($1.14), consensus ($1.20)
Reports Q2 revenue $6.8M, consensus $7.74M.
16:14 EDTVTLVital Therapies reports Q2 EPS (63c), consensus (62c)
"As we approach data lock and analysis of VTI-208 results, we are pleased to report we are on schedule to report topline results later this quarter. VTI-208 is the largest liver support system clinical trial ever conducted, was run on three continents and enrolled 203 subjects. Needless to say we are excitedly awaiting these results," said Terry Winters, Ph.D., CEO and Co-Chairman. Cash and cash equivalents at June 30 totaled $71.9M, compared to $102.2M at December 31, 2014. Based on the current business plan, the company believes it has enough cash to fund the company into the third quarter of 2016, although the company's projections will be highly dependent on the topline results of the VTI-208 clinical trial.
July 29, 2015
16:17 EDTSTAASTAAR Surgical reports Q2 adjusted EPS 0c, consensus (3c)
Subscribe for More Information
06:38 EDTPTCTBioMarin price target raised to $163 from $147 at Piper Jaffray
Subscribe for More Information
July 27, 2015
10:40 EDTBLUEIsis 'most obvious' Biogen takeover target, TheStreet's Feuerstein says
Subscribe for More Information
06:56 EDTVTLVital Therapies to address 'certain misinformation' during Q2 call
Subscribe for More Information
July 22, 2015
09:05 EDTFCSCFibrocell Science 2.58M share Spot Secondary priced at $5.80
Wells Fargo acted as lead book running manager for the offering.
July 21, 2015
19:00 EDTFCSCOn The Fly: After Hours Movers
Subscribe for More Information
16:03 EDTFCSCFibrocell Science files to sell common stock, no amount given
Subscribe for More Information
10:01 EDTANACOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: ASML (ASML) upgraded to Accumulate from Neutral at SNS Securities... Anacor (ANAC) upgraded to Buy from Neutral at Goldman... Artisan Partners (APAM) upgraded to Outperform from Neutral at Credit Suisse... Canadian National (CNI) upgraded to Buy from Hold at Canaccord... General Mills (GIS) upgraded to Outperform from Sector Perform at RBC Capital... Halliburton (HAL) upgraded to Accumulate from Neutral at Global Hunter... Harte-Hanks (HHS) upgraded to Outperform from Market Perform at BMO Capital... MDC Partners (MDCA) upgraded to Overweight from Neutral at Piper Jaffray... SABMiller (SBMRY) upgraded to Buy from Neutral at Nomura... Sanmina (SANM) upgraded to Neutral from Underperform at Longbow... Santander Mexico (BSMX) upgraded to Neutral from Sell at Goldman... Sherwin-Williams (SHW) upgraded to Buy from Neutral at Northcoast... Southwestern Energy (SWN) upgraded to Buy from Neutral at Global Hunter... Verisk Analytics (VRSK) assumed with an Outperform at Keefe Bruyette.
09:21 EDTANACOn The Fly: Pre-market Movers
Subscribe for More Information
06:40 EDTANACAnacor upgraded to Buy from Neutral at Goldman
Subscribe for More Information
July 20, 2015
08:10 EDTFCSCFibrocell Science, Intrexon file IND for FCX-007
Fibrocell Science (FCSC) and Intrexon (XON) announced the submission of an Investigational New Drug, or IND, Application with the FDA for FCX-007, Fibrocell's lead orphan gene-therapy drug candidate for the treatment of recessive dystrophic epidermolysis bullosa, or RDEB.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use